Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 7.4% - Time to Sell?

Key Points

• Tiziana Life Sciences shares fell 7.4% to $1.75 during trading, with a notable drop in trading volume by 18% compared to its average.
• Institutional investors have increased their stakes in Tiziana Life Sciences, with several funds making new purchases totaling over $250,000 in recent quarters.
• The company focuses on developing treatments for diseases in oncology and immunology, with its lead product candidate being Foralumab for various autoimmune conditions.

Shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA - ) were down 7.4% during trading on Tuesday . The company traded as low as $1.73 and last traded at $1.75. Approximately 471,714 shares were traded during trading, a decline of 18% from the average daily volume of 578,578 shares. The stock had previously closed at $1.89.

Tiziana Life Sciences Stock Performance

The stock's 50 day simple moving average is $1.78 and its 200 day simple moving average is $1.39.

Institutional Trading of Tiziana Life Sciences

Several institutional investors and hedge funds have recently modified their holdings of TLSA. Cubist Systematic Strategies LLC purchased a new stake in shares of Tiziana Life Sciences in the first quarter worth approximately $25,000. Bison Wealth LLC bought a new position in shares of Tiziana Life Sciences during the fourth quarter valued at about $30,000. Marshall Wace LLP bought a new position in shares of Tiziana Life Sciences during the second quarter valued at about $39,000. OMERS ADMINISTRATION Corp bought a new position in shares of Tiziana Life Sciences during the first quarter valued at about $156,000. Finally, Geode Capital Management LLC lifted its position in shares of Tiziana Life Sciences by 12.4% during the fourth quarter. Geode Capital Management LLC now owns 245,722 shares of the company's stock valued at $171,000 after purchasing an additional 27,041 shares in the last quarter.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.